FI953565A0 - Uusi antikoagulanttikofaktoriaktiivisuus - Google Patents

Uusi antikoagulanttikofaktoriaktiivisuus

Info

Publication number
FI953565A0
FI953565A0 FI953565A FI953565A FI953565A0 FI 953565 A0 FI953565 A0 FI 953565A0 FI 953565 A FI953565 A FI 953565A FI 953565 A FI953565 A FI 953565A FI 953565 A0 FI953565 A0 FI 953565A0
Authority
FI
Finland
Prior art keywords
activity
apc
protein
component
human
Prior art date
Application number
FI953565A
Other languages
English (en)
Swedish (sv)
Other versions
FI953565A (fi
Inventor
Bjoern Dahlbaeck
Original Assignee
Bjoern Dahlbaeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI953565(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9300300A external-priority patent/SE9300300D0/xx
Priority claimed from SE9302457A external-priority patent/SE9302457D0/xx
Application filed by Bjoern Dahlbaeck filed Critical Bjoern Dahlbaeck
Publication of FI953565A publication Critical patent/FI953565A/fi
Publication of FI953565A0 publication Critical patent/FI953565A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
FI953565A 1993-01-29 1995-07-26 Uusi antikoagulanttikofaktoriaktiivisuus FI953565A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9300300A SE9300300D0 (sv) 1993-01-29 1993-01-29 A novel anticoagulant entity, antibodies reacting specifically with the entity, and diagnostic and therapeutic used of the entity
SE9302457A SE9302457D0 (sv) 1993-07-20 1993-07-20 A novel anticoagulant entity, antibodies reacting specifically with the enety, and diagnostic and therapeutic uses of the entity
PCT/SE1994/000070 WO1994017415A1 (en) 1993-01-29 1994-01-28 Novel anticoagulant cofactor activity

Publications (2)

Publication Number Publication Date
FI953565A FI953565A (fi) 1995-07-26
FI953565A0 true FI953565A0 (fi) 1995-07-26

Family

ID=26661641

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953565A FI953565A0 (fi) 1993-01-29 1995-07-26 Uusi antikoagulanttikofaktoriaktiivisuus

Country Status (17)

Country Link
US (2) US7169572B1 (fi)
EP (1) EP0690991B2 (fi)
JP (1) JPH08506181A (fi)
AT (1) ATE168781T1 (fi)
AU (1) AU690535B2 (fi)
BR (1) BR9406223A (fi)
CA (1) CA2154080C (fi)
CZ (1) CZ184995A3 (fi)
DE (1) DE69411898T3 (fi)
DK (1) DK0690991T4 (fi)
ES (1) ES2119165T5 (fi)
FI (1) FI953565A0 (fi)
GR (1) GR3027697T3 (fi)
HU (1) HUT72191A (fi)
NZ (1) NZ261190A (fi)
PL (1) PL181102B1 (fi)
WO (1) WO1994017415A1 (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181102B1 (pl) * 1993-01-29 2001-05-31 Dahlbaeck Bjoern Sposób oznaczania w próbce funkcjonalnej aktywności wybranego składnika koagulacji krwi
US6518016B1 (en) 1994-02-14 2003-02-11 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
DE4439756C2 (de) * 1994-11-09 2002-07-18 Dade Behring Marburg Gmbh Kalibrator zur Verwendung in Testverfahren zum Nachweis eines defekten Gerinnungsfaktors V
ATE198772T1 (de) * 1994-11-10 2001-02-15 Dade Behring Marburg Gmbh Verfahren zum spezifischen nachweis eines aktivierten gerinnungsfaktors v mit einer erhöhten stabilität gegenüber aktiviertem protein c
US6867045B1 (en) * 1994-11-14 2005-03-15 The Scripps Research Institute Method for diagnosis of thrombotic disorders
ES2157295T5 (es) * 1994-12-23 2005-07-01 Diagnostic Reagents Limited Metodo para diagnosticar trastornos de la coagulacion de la sangre.
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
US5863896A (en) * 1995-11-09 1999-01-26 Immuno Ag Evaluation of substances for altering and for increasing APC response
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
DE19634312A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
CA2328493A1 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
FR2778923B1 (fr) * 1998-05-22 2000-08-18 Stago Diagnostica Compositions utiles comme controle pathologique dans une methode de detection d'une resistance a la proteine c activee, procede de preparation de ces compositions et utilisation dans ladite methode de detection
JP4377207B2 (ja) 2003-11-28 2009-12-02 シスメックス株式会社 血液凝固時間測定方法および血液凝固時間測定用試薬
WO2008067056A2 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
US11650196B2 (en) * 2017-01-06 2023-05-16 Sony Corporation Blood coagulation system analysis apparatus, blood coagulation system analysis system, blood coagulation system analysis method, blood coagulation system analysis program, blood loss prediction apparatus, blood loss prediction system, blood loss prediction method, and blood loss prediction program

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3330699A1 (de) 1983-08-25 1985-03-07 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
JPS60241900A (ja) 1984-05-16 1985-11-30 Nitto Boseki Co Ltd 新規な第Ｘａ因子活性測定用基質
DE3516579A1 (de) 1984-11-19 1986-05-22 Boehringer Mannheim Gmbh, 6800 Mannheim Gerinnungstest auf teststreifen
US4849403A (en) 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
DE3536903A1 (de) 1985-10-16 1987-04-16 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung von protein c
DE3607559A1 (de) 1986-03-07 1987-09-10 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet
US5200322A (en) * 1986-09-19 1993-04-06 Nippon Zoki Pharmaceutical Co., Ltd. Method for assaying protein C and measuring kit for the same
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5055412A (en) 1989-03-21 1991-10-08 Proksch Gary J Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same
IT1230744B (it) * 1989-07-07 1991-10-29 Instrumentation Lab Spa Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano.
US5051357A (en) 1989-07-14 1991-09-24 Board Of Trustees Operating Michigan State University Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
WO1991001383A1 (en) 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
SE464135B (sv) 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5169786A (en) 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
US5314695A (en) 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AT395597B (de) 1991-01-25 1993-01-25 Immuno Ag Reagens zur bestimmung von faktor viii-aktivitaet
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
ES2081618T5 (es) * 1991-11-13 2005-09-01 T.A.C. Thrombosis And Coagulation Aktiebolag Metodo para diagnosticar anomalias de la coagulacion de la sangre.
SE470274B (sv) 1991-11-13 1993-12-20 Bjoern Dahlbaeck Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar
US5308756A (en) * 1991-11-20 1994-05-03 Baxter Diagnostics Inc. Protein S chromogenic assay
PL181102B1 (pl) * 1993-01-29 2001-05-31 Dahlbaeck Bjoern Sposób oznaczania w próbce funkcjonalnej aktywności wybranego składnika koagulacji krwi
EP0656424B1 (de) * 1993-12-03 2002-02-06 Baxter Aktiengesellschaft Test zur Bestimmung der Empfindlichkeit gegenüber aktiviertem Protein C
DE4427785A1 (de) * 1994-08-08 1996-02-15 Behringwerke Ag Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems
DE4439756C2 (de) * 1994-11-09 2002-07-18 Dade Behring Marburg Gmbh Kalibrator zur Verwendung in Testverfahren zum Nachweis eines defekten Gerinnungsfaktors V
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US5780255A (en) * 1995-06-09 1998-07-14 Instrumentation Laboratory, S.P.A. Protein C pathway screening test
US20030143759A1 (en) 1995-10-20 2003-07-31 Bjorn Dahlback Assays for determining anticoagulant cofactor activity
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism

Also Published As

Publication number Publication date
CA2154080A1 (en) 1994-08-04
CA2154080C (en) 2006-03-21
ES2119165T3 (es) 1998-10-01
PL181102B1 (pl) 2001-05-31
BR9406223A (pt) 1996-01-09
DK0690991T4 (da) 2004-02-16
ATE168781T1 (de) 1998-08-15
EP0690991A1 (en) 1996-01-10
HU9502190D0 (en) 1995-09-28
FI953565A (fi) 1995-07-26
NZ261190A (en) 1997-12-19
CZ184995A3 (en) 1996-03-13
US20070212743A1 (en) 2007-09-13
GR3027697T3 (en) 1998-11-30
US7169572B1 (en) 2007-01-30
HUT72191A (en) 1996-03-28
DK0690991T3 (da) 1999-02-01
EP0690991B2 (en) 2004-01-14
PL310050A1 (en) 1995-11-13
AU5982794A (en) 1994-08-15
DE69411898T2 (de) 1998-12-17
JPH08506181A (ja) 1996-07-02
EP0690991B1 (en) 1998-07-22
ES2119165T5 (es) 2004-07-01
WO1994017415A1 (en) 1994-08-04
DE69411898T3 (de) 2004-07-08
DE69411898D1 (de) 1998-08-27
AU690535B2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
DK0690991T3 (da) Ny antikoagulant-cofaktor-aktivitet
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
DK0420332T3 (da) Fremgangsmåde til bestemmelse af det endogene trombinpotentiale af plasma og blod, samt et kit til anvendelse ved fremgangsmåden
DK0947585T3 (da) Forbedret in vitro-fremgangsmåde, kits og reagenser til screening for blodkoagulationsdefekter
TR200000565T2 (tr) Biyolojik örneklerdeki analiz bileşenlerinin hızlı analizi için yöntem
DK1389241T3 (da) Polynucleotid-sekventeringsfremgangsmåde
DK0944731T3 (da) Enzymsensor
WO2002003075A3 (en) Methods for detecting activity of clotting factors
ES2072243T3 (es) Prueba de coagulacion cuantitativa para medir la concentracion de factor vii activo.
RU2002113055A (ru) Тестирующая полоска с реагентом для определения содержания анализируемого вещества
ATE42342T1 (de) Verfahren zur alpha-amylasebestimmung und reagenssatz.
DE69214906D1 (de) Homogene Immunotests unter Verwendung von Enzym-Inhibitoren
AU3772495A (en) Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state
DK0696642T3 (da) Fremgangsmåde til påvisning af forstyrrelser i protein C/protein S-systemet
ATE234467T1 (de) Immunoassay von vollblutproben
DK173090D0 (da) Forbedrede ekstraktionsmetoder til fremstilling af thromboplastinreagenser
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
FI901468A0 (fi) Testipakkaus entsyymien määritykseen ja määritysmenetelmä
NO920624L (no) Reagens for paavisning av fibrinolytisk aktivitet
DK0587090T3 (da) Fremgangsmåde til bestemmelse af thromboseforårsagende lupus-antikoagulat-antistoffer.
ATE175243T1 (de) Verwendung von prothrombinfragmenten
EP0188008A3 (de) Verfahren zur Bestimmung der Aktivität des Komplementsystems des Blutes
ATE200710T1 (de) Verfahren zur diagnose von blutgerinnungsstörungen
SE9203159D0 (sv) Partikel suspension
TH52313A (th) แถบทดสอบที่มีรีเอเจนต์สำหรับการกำหนดสารวิเคราะห์ออกมา

Legal Events

Date Code Title Description
FD Application lapsed